A pivotal Phase 3, single-center, open-label, randomized study to compare the PK and pharmacodynamics (PD) of single and repeat doses of Anaphylm (AQST-109 ) versus single and repeat doses of the epinephrine intra-muscular (IM) injection and epinephrine autoinjectors (EpiPen and Auvi-Q) in healthy adult subjects
Latest Information Update: 23 Oct 2026
At a glance
- Drugs Dibutepinephrine (Primary) ; Dibutepinephrine (Primary)
- Indications Anaphylaxis
- Focus Pharmacokinetics; Registrational
- Sponsors Aquestive Therapeutics
Most Recent Events
- 15 Oct 2026 According to an Aquestive Therapeutics media release, the company continues to advance its ex-U.S. regulatory progress for Anaphylm and remains on track to complete its New Drug Submission to Health Canada in Q4 2026.
- 15 Oct 2026 According to an Aquestive Therapeutics media release, the U.S. Food and Drug Administration (FDA) has acknowledged its resubmission of the New Drug Application (NDA) for Anaphylm (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis, as complete and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 16, 2027, in keeping with the FDA's classification of the resubmission as a Class 2 response.
- 17 Sep 2026 According to an Aquestive Therapeutics media release, the company has resubmitted its New Drug Application (NDA) to the U.S. FDA for Anaphylm (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis.